Considerations in establishing a post-mortem brain and tissue bank for the study of myalgic encephalomyelitis/chronic fatigue syndrome: a proposed protocol by Luis Nacul et al.
Nacul et al. BMC Research Notes 2014, 7:370
http://www.biomedcentral.com/1756-0500/7/370TECHNICAL NOTE Open AccessConsiderations in establishing a post-mortem
brain and tissue bank for the study of myalgic
encephalomyelitis/chronic fatigue syndrome:
a proposed protocol
Luis Nacul1*, Dominic G O’Donovan2, Eliana M Lacerda1, Djordje Gveric3, Kirstin Goldring4, Alison Hall5,
Erinna Bowman1 and Derek Pheby6Abstract
Background: Our aim, having previously investigated through a qualitative study involving extensive discussions
with experts and patients the issues involved in establishing and maintaining a disease specific brain and tissue
bank for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), was to develop a protocol for a UK ME/CFS
repository of high quality human tissue from well characterised subjects with ME/CFS and controls suitable for a
broad range of research applications. This would involve a specific donor program coupled with rapid tissue collection
and processing, supplemented by comprehensive prospectively collected clinical, laboratory and self-assessment data
from cases and controls.
Findings: We reviewed the operations of existing tissue banks from published literature and from their internal
protocols and standard operating procedures (SOPs). On this basis, we developed the protocol presented here,
which was designed to meet high technical and ethical standards and legal requirements and was based on
recommendations of the MRC UK Brain Banks Network. The facility would be most efficient and cost-effective
if incorporated into an existing tissue bank. Tissue collection would be rapid and follow robust protocols to
ensure preservation sufficient for a wide range of research uses. A central tissue bank would have resources
both for wide-scale donor recruitment and rapid response to donor death for prompt harvesting and
processing of tissue.
Conclusion: An ME/CFS brain and tissue bank could be established using this protocol. Success would depend on
careful consideration of logistic, technical, legal and ethical issues, continuous consultation with patients and the
donor population, and a sustainable model of funding ideally involving research councils, health services, and
patient charities. This initiative could revolutionise the understanding of this still poorly-understood disease and
enhance development of diagnostic biomarkers and treatments.
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Introduction
Myalgic encephalomyelitis (or encephalopathy)/chronic
fatigue syndrome (ME/CFS) is classified by the World
Health Organization (WHO) as a neurological disorder
(ICD10, G.93.3) [1]. Its aetiology and pathogenesis have
not been elucidated, although increasing evidence points
to nervous system abnormalities [2-11] and immuno-
logical dysregulation [12-17]. The diagnosis is clinical
and based on a history of unexplained persistent or re-
current incapacitating fatigue for over six months ac-
companied by variable symptoms, leading to substantial
reductions in previous levels of occupational, educational,
social and personal activities [18,19], often to moderate or
severe disability. There are currently no widely accepted
confirmatory diagnostic tests or specific treatments.
Post-mortem examinations have greatly helped to clar-
ify the aetiology and pathogenesis of a wide range of
medical disorders, e.g. Creutzfeldt-Jakob disease (CJD)
and Parkinson’s disease, opening possibilities for better
diagnosis and in many cases treatment. The poor under-
standing and lack of consensus on the causes and patho-
physiological mechanisms involved in ME/CFS and the
lack of specific animal models suggest its suitability for
study through pathology. However, and rather surpris-
ingly, only a very small number of (ad hoc) pathological
studies have been conducted in people who have died
with ME/CFS. A few but not all autopsies conducted
have shown nervous system abnormalities, including
inflammation in the dorsal root ganglia [2] and evi-
dence of viral encephalitis [20,21]. These do not, how-
ever, constitute sufficient evidence to confirm the role of
the central or peripheral nervous system in its aetiology or
pathogenesis.
Calls for brain banks to study ME/CFS have been made
in the US [22] and Australia [23] as early as 1996 and
1999. The CFS Peer Reviews for the Centers for Disease
Control (CDC) in the US recommended the establishment
of a CFS patient brain bank for “neuropathological analysis
for tissues not available by other mechanisms” [24]. Never-
theless no action from the CDC or others has yet resulted
from that recommendation, and no initiatives have been
reported towards systematically addressing the use of path-
ology for the study of ME/CFS. The only related initiative
has come from the Sun Health Research Institute in Sun
City, Arizona, US [25], which reported the creation in 1997
of the first and still incipient tissue bank for the study
of fibromyalgia, a condition closely related to ME/CFS. A
study carried out by two of the authors (LN, EL) confirmed
that most patients with ME/CFS favour the establishment
of a post-mortem tissue bank [26].
We hypothesise that the better understanding of the
aetiology and pathology of ME/CFS following systematic
tissue collection and examination would lead to improveddiagnosis and disease recognition. Moreover, it would allow
the development of new treatment options and interven-
tions specifically targeting possible causes of disease and
thus potentially resulting in clinical improvement of pa-
tients. This paper discusses considerations in setting up
and maintaining a brain and tissue bank for the study of
ME/CFS and outlines a protocol for accomplishing this.
The aim of the study is to review the fundamental re-
quirements for and to develop a protocol for establishing
an internationally unique facility of high quality human
tissue from well characterised subjects with ME/CFS
and controls, suitable for a broad range of research ap-
plications. This will be achieved through a specific donor
program coupled with a system for rapid tissue collection
and processing, supplemented by comprehensive prospect-
ively collected clinical, laboratory and self-assessment data
from cases and controls.
Procedures will meet high technical and ethical stan-
dards and legal requirements in relation to recruitment
and follow-up of donors and the collection, handling,
preservation and disposal of tissue. The protocol and
procedures adopted will be based on the recommenda-
tions of the MRC UK brain banks network [27], of which
the ME/CFS Tissue Bank will become a member. We
will develop close collaboration with other tissue banks to
facilitate the supply of control CNS tissue for research,
subject to appropriate consents being available.
Specific objectives include:
 To establish a cohort and donor scheme of well
characterized cases of ME/CFS and controls for
eventual retrieval of nervous system and other
tissue post-mortem;
 To establish a post-mortem brain and tissue bank
comprising samples from well characterized cases of
ME/CFS and controls;
 To enable high quality pathological research in
ME/CFS and identify biomarkers; and
 To disseminate the resource to the international
research community and other potential users.
The study, which was approved by the London School
of Hygiene and Tropical Medicine (LSHTM) Ethics
Committee, did not involve any human subjects, so no
consent was required or obtained.
Materials and methods
We developed a protocol for a UK-based repository of
tissues from people with ME/CFS. This resulted from
extensive discussions with a range of experts and pa-
tients and the results of a qualitative studya reported in
detail elsewhere [26], which aimed at determining the
acceptability and feasibility of establishing a tissue bank
for the study of ME/CFS. These were complemented by
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of internal protocols and standard operating procedures
(SOPs) from established tissue banks. This qualitative
study was approved by the London School of Hygiene
and Tropical Medicine (LSHTM) Ethics Committee and
was performed in accordance with the ethical standards
laid down in the Declaration of Helsinki 2008. All partic-
ipants gave prior informed consent to the use of their in-
puts in the preparation of reports.
Results
We were able to establish the desirability and feasibility
of establishing a tissue bank for the study of ME/CFS
and to develop a protocol for its establishment. Our
conclusions were that this would best be met by situat-
ing the ME/CFS Tissue Bank within an operational tis-
sue bank, thus benefiting from existing infrastructure
and experience whilst optimizing the use of resources.
This protocol is generic and could be adopted by any ap-
propriate facility within the UK or, with relevant adap-
tions, internationally. The Addenbrooke’s Hospital Brain
and Tissue Bank in Cambridge is very well placed for
this purpose due to its long-term experience in tissue
banking and previous involvement in ME/CFS research,
and is intended as the initial site for the ME/CFS Tissue
Bank. In addition, the involvement of patients and their
representatives and particularly charities working with
people with ME/CFS (PWME) would provide the neces-
sary framework to ensure that the research is truly par-
ticipatory and ongoing recruitment is safeguarding the
long term sustainability of the Bank.
The protocol we developed as a result of this study is
detailed below:
Overview of procedures
Sources and procedures for recruitment of tissue donors
Potential donors will be able to access information about
the Tissue Bank and targeted-donor scheme primarily
from the project webpage and from GPs and other
health professionals, including at selected NHS ME/CFS
clinics, particularly those situated within the catchment
area of the Tissue Bank, i.e. in the East of England. De-
pending on availability of funding, the intention would
be to expand the catchment area to include other re-
gions of the country, with the potential to include other
services as receptors of tissues. Other sources of partici-
pants may include disease specific charities and support
groups, related newsletters and magazines, scientific and
group meetings with patients and from GPs and other
health professionals, however, these avenues of publicity
and any expansion from the geographical area of recruit-
ment, could only be executed in line with the capacity of
the team to absorb the potentially high levels of demand
for donations. Information packs will be sent to potentialdonors in response to requests for information. These will
include an information booklet, the donor consent form, a
form for close relatives of the donor to complete indicating
their agreement with the proposed donation, a health ques-
tionnaire, our latest newsletter, and a self addressed and
stamped or freepost envelope. Potential donors, including
cases and controls, will have the opportunity to phone
Tissue Bank staff to clarify any doubts before deciding to
enrol. In addition, they will have the opportunity to discuss
any issues directly with the Tissue Bank of staff collecting
their blood samples. Those deciding to register as donors
will be issued a donor card containing the contact details
of the Tissue Bank and will be asked to inform their close
relatives and GPs of their donor status.
Inclusion and exclusion criteria for donors
Donors will include individuals over 18 years old with a
confirmed diagnosis of ME/CFS for at least two years
using the Fukuda (‘CDC-94’) and Canadian Consensus
Criteria, which are standard, widely-accepted case defini-
tions [18,19], as ascertained by a health professional with
knowledge of ME/CFS, e.g. a specialist working in an
ME/CFS clinic or a GP with a special interest in ME/
CFS. We will ask patients to confirm they have been di-
agnosed by a medical professional with expertise in ME/
CFS and to include a letter from their GP or another
health professional confirming their diagnosis has been
formally made. Controls will include individuals of the
same age group and without present or past history of
chronic fatigue or other neurological, psychiatric, im-
mune and inflammatory diseases or major morbidity,
such as cancer. These will be sought from friends, rela-
tives of cases and other volunteers. Since the control do-
nors will be recruited as a direct result of their relationship
with affected individuals, recruitment of control donors
would be necessarily targeted at those who have knowledge
of (and possibly indirect experience of) the condition. We
will ensure that consent by control subjects is given freely,
that they have sufficient time for reflection, and that they
can access more information about what is involved in the
Tissue Bank independently of cases in simple and straight-
forward ways, using the same channels of information and
response to queries as cases.
Donors will also be asked to give consent as ‘control
subjects’ for studies conducted for other diseases, in
connection with other tissue banks in the network. Indi-
viduals with confirmed previous ME/CFS, but who are
asymptomatic and no longer fulfil diagnostic criteria,
will be accepted as donors and form a separate group
(controls with previous ME/CFS). The same procedure
will apply to the minority of those who had ME/CFS at
recruitment, but who no longer have the condition at
the time of death. We will encourage recruitment of
family members with ME/CFS as cases.
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Recruitment procedures
A self-completed recruitment form will establish detailed
information on diagnosis, clinical symptoms, potential
exposures and socio-demographic variables. Donors will
be invited to donate up to 100 ml of blood for freezing
and long-term storageb, which may be used for specific
research projects and as a further source of information
for the characterisation of cases post-mortem.
Follow–up of donors
Donors will be followed up at least every two years
through postal or electronic questionnaires. Information
from the questionnaires will be complemented by clin-
ical data, e.g. those provided to the ME/CFS Disease
Register and UK ME/CFS Biobank, clinical notes from
assessments by GPs, research physicians and specialist
doctors, and from laboratory and other tests, where ap-
propriate. This complementary information will usually
be obtained post-mortem.
Table 1 illustrates the potential yield of effective tissue
donations over 5 years, according to the number of
PWME who register as donors (as a percentage of total
number of people estimated to have the condition),
based on an average UK population mortality. A similar
yield for controls of the same age group and sex could
be expected within the same periods of time. The actual
numbers would depend on resources and interest.
Post-mortem procedures
Communication of death, inclusion and exclusion criteria
The ME/CFS Tissue Bank will adopt a rapid response
system following the death of a registered donor. The
system will usually be initiated by a relative or carer tele-
phoning the 24 hr emergency donor line (information
found on the donor card), which is linked to a pager sys-
tem, notifying the Tissue Bank of the death of a registered
donor and leaving contact details. In response to the page
a member of the Tissue Bank team will immediately call
the contact person for further details. An on-call rota sys-
tem will guarantee that the Tissue Bank will answer every
call made to the emergency donor line promptly.
Tissue also will be collected from those who have
not previously registered when possible, for example, ifTable 1 Expected maximum number of effective tissue
donations by time from recruitment in the donor scheme
Number of donors (% of PWME) 1 year 2 years 5 years
1,500 (1%) 3 6 20
3,000 (2%) 6 11 41
19,000 (5%) 15 29 102
15,000 (10%) 30 57 204
(PWME = people with ME/CFS).family members contact the ME/CFS Tissue Bank team at
the time of ‘imminent or actual death’. This will be subject
to the requirement of the Human Tissue Act that ‘a deci-
sion of [the potential donor] to consent to the activity was
in force immediately before he died’c [28]. In these cases,
donations will be arranged if the documented agreement
of relatives and tissue procurement can be organised
within the appropriate time frame.
For all donors, tissue donations will not be possible in
the following circumstances: (i) if the death has been re-
ferred to the coroner and the coroner does not authorise
the donation to proceed, or the tissue will not be avail-
able in the appropriate time frame, for example due to a
prolonged post-mortem interval; and (ii) if it is possible
that there is the presence of an infectious disease such
as CJD, HIV, MRSA, septicaemia, tuberculosis, or hepa-
titis B or C.
Acquisition and transportation of bodies, tissues and
organs to the Tissue Bank
Donors who live in the Tissue Bank area will, in the
event of their death, have their whole body transported
to the local mortuary for the autopsy and retrieval of
relevant tissue samples [29]. On all other occasions tis-
sues will be harvested in a mortuary close to the place of
death. Tissues will be either collected as fresh samples
from the mortuary by a member of the Tissue Bank team
or transported to the tissue bank from the mortuary by
authorised couriers following an appropriate period of tis-
sue fixation. We aim to collect our cases within 24 hours
of death whenever possible with a 5 day maximum post
mortem interval (if refrigerated for histology) to ensure the
suitability of tissue for the widest possible range of scien-
tific techniques. Nevertheless we appreciate the difficulties
in achieving a very rapid collection of samples, particularly
in cases where coroner’s involvement is required, and
therefore will consider the inclusion of cases with longer
interval periods from death to retrieval of tissues.
Tissue preparation and storage
We aim to provide tissue specimens that have been opti-
mally prepared and stored for a variety of techniques as
follows:
i. Fresh frozen tissue blocks for mRNA, protein
extraction and PCR techniques;
ii. Fresh frozen tissue for cryosectioning for in situ
hybridisation, immunohistochemistry and cell-based
adhesion assays; and
iii. Formaldehyde fixed and paraffin embedded tissue
blocks for histology and immunohistochemistry.
For techniques less commonly used, such as ultra-
structural studies and cell culture from fresh tissue,
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tion will be agreed following discussions of requirements
with the research investigators concerned.
Outline of tissue processing
Immediately upon arrival, tissues will be weighed and
the pH of tissue and cerebrospinal fluid (CSF) sample
measured. A digital photograph of the lateral, inferior
and superior views of the intact brain and lateral views
of the spinal cord will be taken at this stage. Any gross
pathological changes will be documented. When the brain
is processed the whole brain is cut in ‘half ’ by a sagittal
cut, resulting in half the brain being fixed and half
remaining for processing for freezing. In each case at the
time of processing a further cut is made through the brain-
stem to separate the brain stem and cerebellum from the
rest of the brain. Then the cerebral hemisphere and the
cerebellar hemispheres are sliced and blocked independ-
ently. A small piece of tissue (<1 cm3) will be taken for
total RNA extraction using the guanidinium thiocyanate
and CsCl method [30]. This will be used to determine the
degree of mRNA preservation for each brain and given an
(RIN) number. Following 6 weeks’ fixation, 1 cm thick cor-
onal sections will be sectioned according to international
standards [31,32] and digitally photographed before further
processing. Blocks from the ‘half ’ brain which is frozen will
all be photographed and stored. Hence, there is the poten-
tial to retrieve samples retained from the whole or one side
of the brain. For long-term storage, tissue blocks will be
placed in air-tight containers and stored in −80°C freezers
with CO2 backup and 24 hr monitoring using remote
equipment linked to the on-call pager system.
Clinical and tissue bank databases
Information gained during the recruitment of donors,
the harvesting of brains and the subsequent tissue ana-
lysis will be kept securely as three datasets linked in a
relational password protected database, which will be
accessed only by selected members of the tissue bank
team. The first dataset will comprise detailed informa-
tion of past clinical history (taken from follow-up of do-
nors and complemented by retrospective clinical data
obtained from the attending physician’s post-mortem).
The GP and specialist notes will be abstracted and added
to this dataset. Each donor will be given a number, which
will be translated into a brain tissue (donation) number at
autopsy.
The second dataset will contain information obtained
at autopsy concerning patient details at time of death,
macroscopic brain analysis, documentation of slice and
block nomenclature. Information obtained from the rou-
tine neuropathological screening and further microscopic
analysis of tissues will be added to this dataset when it be-
comes available.The third dataset will be the image database containing
digital images of the gross brain appearance (4 images per
brain), images of the whole coronal slices (20–30 images
per brain), images of the blocked slices (both fixed and
frozen; 20–30 images) and microscopic images of the
routine pathological screening.
This database design will allow secure and fast sharing
of information and easy transfer of information between
datasets. The databases will be fully searchable using ad-
equate query language and updated as required [33].
Scientific strategy
The post-mortem ME/CFS Tissue Bank team will con-
duct research with tissues collected from donors and
controls, mainly investigating evidence of brain and
spinal cord (and its dorsal root ganglia) inflammation
and infection. In addition, tissues will be made available
to researchers conducting ethically approved studies in
the UK and internationally, and following evaluation and
approval by a Steering Committee, whose constituents
will include professionals with experience in ME/CFS,
pathologists, ethicists, patients, and their representatives.
Future research will be dictated by advances in scientific
knowledge and according to research groups’ interest
and expertise. We will develop closer collaboration with
other tissue banks in the UK and abroad to facilitate the
supply of tissues for both cases and control subjects and
to support a wide range of research activities.
Governance and ethical issues
The operation of the tissue bank
The collection and use of human tissue samples for re-
search raises a number of legal and ethical issues. In the
past, particular concern has been expressed about the
use of post-mortem samples without consent, and in re-
sponse, legislation has been enacted in the UK to establish
a framework for obtaining consent to address this issue
[28]. The legislation also establishes systems for licensing
tissue banks and for ensuring that the relevant legislation
and codes of practice are being adhered to. By using an
established tissue bank, the steering committee can be
confident that all relevant conditions have been satisfied.
Another means of minimising potential concerns from
donors and their families is to promote transparency in
the methods and procedures used so as to prevent po-
tential ethical problems; doing so may also optimise re-
cruitment of donors and research outputs. One way this
has been achieved to date is by involving patients and
other relevant stakeholders in all stages of the process,
starting with the planning of the Tissue Bank. This par-
ticipatory approach will be continued with the imple-
mentation and evaluation of the Tissue Bank.
Standard operating procedures will be based on well
established procedures and the best available international
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on behalf of the tissue bank staff will be required to
complete written agreements detailing the procedures for
samples to be collected, initial processing and storage,
transport of samples to a central storage facility, and the
protocol for tissue examination. Strict procedures will be
followed in relation to consent, data protection, and other
legal and ethical issues, including Human Tissue Authority
licensing. Researchers processing tissue from a donor will
be required to ensure that a valid consent covering all pro-
posed uses of tissue has been obtained. Researchers will
also be required to keep patient identifiable information
confidential as a contractual condition.
Electronic sharing of data will be over secure net-
works, and will, wherever possible, only include coded
information on the identity of the donor. Access to these
networks will be password protected. All paper records
detailing the encryption key will be kept locked on hos-
pital or university premises.
Arrangements for follow-up of prospective donors
Although there is a risk that prospective donors might
find follow-up intrusive, the arrangements for follow-up
will be fully documented in the information booklet pro-
vided at the outset. At each point of contact, individuals
will be reminded of their continuing rights to withdraw
should they so wish. They will also be reminded that
they can withdraw without compromising or affecting
the medical care that might be available to them. If a po-
tential donor decides to withdraw from the register of
prospective donors, any data collected prior to with-
drawal, as well as all retrievable biological samples, will
be destroyed.
Consent form and status of tissue samples
The information and consent forms will make clear to
prospective donors that their tissue will be treated as a
‘gift’ to the Tissue Bank and that they will not retain any
rights of ownership over the tissue (including any intel-
lectual property rights that may be generated through
research on those samples). The consent form will de-
scribe in general terms the scope of the possible research
uses and the types of tissue and data that might be col-
lected. It will also include information about how sam-
ples and data will be encrypted and the measures taken
to protect participants’ confidentiality, and on the re-
stricted access of the databases to selected members of
the Research and Tissue Bank teams. Where appropri-
ate, it might also refer to samples or data being sent to
jurisdictions which have less robust data protection re-
gimes than exist in the UK. Where samples are released
to researchers outside the research team, the terms of
use will be set out in a licence agreement. This agree-
ment is likely to include that when samples are providedto researchers by the Tissue Bank, it will be on a ‘not for
profit’ basis. However, where appropriate, administrative
fees may be charged to cover the costs of collecting, pro-
cessing, handling, and shipping samples, including extra
costs incurred in sending samples outside the UK, where
applicable. It will also provide that patient confidentiality
must be respected.
General and ethical oversight
A Steering Group will be formed with members including
potential donors with ME/CFS and their representatives, e.
g. carers; ME/CFS charity members; other lay-members,
such as those from patients and public involvement groups
and or others with interest in human research and ethics;
experts in pathology, ME/CFS clinical care and research;
and lawyers and ethicists with experience in Human Tissue
legislation. The group will meet every 4 months to oversee
project developments and to deliberate on requests from
researchers for tissue provision.
The success of the Tissue Bank will be judged on the
number of patients and controls recruited into the donor
program, number of donations, quality of post-mortem
tissues, number of research projects supplied with tissue,
number and quality of publications and communications
resulting from such research, and feedback from users
and researchers as to the level of service from the Tissue
Bank.
Discussion
The Cambridge Brain Bank, situated at Addenbrooke’s
Hospital (Cambridge University Hospitals NHS Foun-
dation) is the longest running Brain Bank in the UK
[34]. It was established in 1974 to enable research into
nervous system disorders such as dementia (Alzheimer’s,
fronto-temporal), motor neurone disease, Huntington’s
disease, multiple sclerosis and others.
Since then, various other brain banks have been created
and more recently most collections at Addenbrooke’s
have been obtained from patients at that hospital and
from residents in Cambridgeshire and East Anglia. Its
experience in tissue management, status as a centre of
reference, and full compliance with Human Tissue
Authority regulations make it particularly suitable to
host the ME/CFS Tissue Bank, which will benefit from
its existing well established infrastructure and resources
and also from the infrastructure created for the ME/
CFS Disease Register [35]d. Membership of the MRC
UK will add value to the Tissue Bank and enable it to
benefit from and contribute to existing initiatives and
proposed developments of the national strategy for the
collection of control brain material [27], which is often
in short supply.
The still poor understanding of the pathophysiology
and aetiology of ME/CFS, added to the difficulties of
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mal models, make it particularly suited for post-mortem
pathology studies. This is especially true in light of re-
cent methodological advances in pathology, genomics
and proteomics, which enhance the potential of biomed-
ical research. There has been growing evidence pointing
to central nervous and autonomic nervous system dys-
functions and disrupted immunity, including impaired
functioning of NK-cells and increased levels of pro-
inflammatory cytokines. These abnormalities may be
triggered by viral infections and other stressors, and pos-
sibly by persistent infection. The pathoaetiology of ME/
CFS has been reviewed by Shepherd and Chaudhuri
[36]. Nevertheless, a very small number of studies on the
neuropathology of ME/CFS have been conducted so far.
One of the authors (DGOD) at Addenbrooke’s Hospital
demonstrated inflammatory changes at the dorsal root
ganglia in post-mortem samples of affected patients [37].
The neurosensorial tract changes found are compatible
with the central origin pain and fatigue experienced by
patients. Further evidence from neurological involve-
ment comes from brain pathology case studies [2,20,21],
neuroimaging studies [3,4,7-9,38,39] and the many CNS-
type symptoms, such as cognitive dysfunction, hyperacusis,
photophobia and headache presented by patients [8,38,40].
However, the abnormalities and mechanisms behind clin-
ical and imaging findings still require elucidation through
pathology studies, something that would be enabled by the
proposed brain and tissue bank and the generation of a siz-
able number of donations.
ME/CFS poses unique challenges. It appears to be a
heterogeneous condition with no confirmatory diagnos-
tic tests or neuropathological markers. Its study has been
hampered by the multitude and lack of specificity of
diagnostic criteria in use, which are based mainly on re-
ported symptoms. Good clinical data from donors and
the linking of pathological with clinical and laboratory
data will enable the search for a pathological biomarker
at the same time as the development of better diagnostic
criteria and sub-grouping of cases according to clinical
and pathological findings.
Our initiative will help address not only the tremen-
dous gaps in knowledge in ME/CFS, but also the general
scarcity of CNS ‘control’ tissues, specifically through the
sharing of tissues within brain tissue bank networks.
The outputs will be enhanced by robust methods, and
the use of protocols common to other brain and tissue
banks.
For optimum results, we will strive to minimise the
post-mortem interval, which for deaths occurring within
the geographical area covered by the Tissue Bank will be
helped by the relationships developed with local coro-
ners/mortuaries and the possibility of quick transfer of
whole bodies for immediate processing by a dedicatedteam. Moreover, for deaths occurring outside the Tissue
Bank coverage area, it will be possible for a member of the
research team to travel to the site and rapidly transport
material to the Tissue Bank laboratory. This will maximise
the potential for a wide range of investigations, including
molecular studies and those requiring optimum preserva-
tion of the biological and chemical nature of tissue.
This proposal has benefited from extensive discussions
with individuals with ME/CFS and charities working
in this field. These discussions helped form the donor
programme strategy and research protocol and highlighted
areas where further debate was required. Participatory re-
search ensures the desires and needs of patients are ad-
dressed. It also optimises the acceptability, appropriateness,
effectiveness and overall quality of research [26]. ME/CFS
charities are already involved in seeking funding for the
long term sustainability of the Tissue Bank once support
for its implementation from research councils and the
NHS is ensured.
Conclusion
In conclusion, we have established the need for the struc-
tured collection and examination of nervous system hu-
man tissue of people who have died with ME/CFS. Based
on the experience at Addenbrooke’s Hospital and other
brain banks, and building on information given by ex-
perts and by patients themselves, we have developed a
protocol for the first ME/CFS Tissue Bank in the world,
including carefully chosen approaches for recruiting and
following up donors and for collecting, storing and exam-
ining post-mortem tissue samples. This initiative has the
potential to revolutionise the understanding of this still
poorly recognised disease and greatly help the develop-
ment of more precise case definitions, diagnostic bio-
markers, and treatments.
Endnotes
aThe qualitative study included interviews with ‘key in-
formants’ and focus group discussions with people with
ME/CFS and the results were reviewed in a workshop
with a group of experts, including ME/CFS clinicians,
researchers, epidemiologists, pathologists, a lawyer and
patient representatives.
bThese patients will be invited to become part of the
linked UK ME/CFS Biobank.
cThe Human Tissue Act, at s3(6)(c), distinguishes be-
tween consent for anatomical examination for which a
written consent is required and consent for research for
which an oral consent or the consent of a ‘qualifying
relative’ is sufficient [28].
dThis is an ongoing project aimed at the population
wide recruitment of people with ME/CFS for clinical
and epidemiological studies and at being a source of
cases for future research involvement.
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